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Abstract: Steroidal neuromuscular blocking agents (NMBAs), such as rocuronium, are widely 
used in clinical anesthesia and emergency medicine to facilitate endotracheal intubation and 
artiﬁ  cial ventilation and to allow surgical access to body cavities. Reversal of neuromuscular 
blockade is important for the acceleration of patient recovery and prevention of postoperative 
residual neuromuscular blockade and reduces the incidence of severe morbidity and mortality 
associated with anesthesia management. Sugammadex is the ﬁ  rst selective relaxant binding agent 
(SRBA) and has been designed to reverse the steroidal neuromuscular blocking drug rocuronium. 
Encapsulation of the rocuronium molecule by sugammadex results in a rapid decrease in free 
rocuronium in the plasma and subsequently at the nicotinic receptor at the motor endplate. After 
encapsulation, rocuronium is not available to bind to the nicotinic receptor in the neuromuscular 
junction. This promotes the liberation of acetylcholine receptors, and muscle activity reappears. 
This new concept of reversal of neuromuscular block induced by rocuronium (or vecuronium) 
led to impressive results in animal and phase 1 and 2 studies. Sugammadex is currently in phase 
3 clinical studies and may be commercially available by 2008.
Keywords: neuromuscular block, rocuronium, neuromuscular blocking agent, sugammadex, 
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Introduction
Steroidal neuromuscular blocking agents (NMBAs), such as rocuronium, are widely 
used in clinical anesthesia and emergency medicine to facilitate endotracheal intuba-
tion and artiﬁ  cial ventilation and to allow surgical access to body cavities (Hunter 
1995). Although the use of NMBAs has signiﬁ  cantly reduced the incidence of 
laryngopharyngeal lesions due to endotracheal intubation, their use is still associated 
with higher morbidity and mortality compared with anesthetic techniques that do not 
use NMBAs (Pedersen et al 1992; Shorten 1993; Mencke et al 2003). This is mainly 
attributable to the development of postoperative residual neuromuscular blockade, 
resulting in hypoventilation, airway obstruction, and hypoxia (Pedersen et al 1992; 
Shorten 1993). Reversal of neuromuscular blockade is important for the acceleration 
of patient recovery and prevention of postoperative residual neuromuscular blockade, 
and reduces the incidence of severe morbidity and mortality associated with anesthesia 
management (Arbous et al 2005).
At present, the reversal of neuromuscular blockade is achieved by the administration 
of cholinesterase inhibitors (neostigmine, edrophonium, or pyridostigmine) (Osmer et al 
1996). Importantly, cholinesterase inhibitors have a number of undesirable side-effects 
(bradycardia, bronchoconstriction, hypersalivation, abdominal cramps and nausea and 
vomiting) (Van Vlymen and Parlow 1997) which can be counteracted by co-administration 
of muscarinic antagonists (atropine or glycopyrrolate) (Osmer et al 1996; van Vlymen and 
Parlow 1997). However, muscarinic antagonists also have side-effects (blurred vision, 
dry mouth, and tachycardia) (van Vlymen and Parlow 1997; Zhang 2003). Furthermore, Neuropsychiatric Disease and Treatment 2007:3(5) 540
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due to their mechanism of action, cholinesterase inhibitors 
are not capable of reversing deeper levels of neuromuscular 
blockade (Booij et al 2002; Zhang 2003). Return of muscle 
paralysis after apparent reversal of neuromuscular block by 
cholinesterase inhibitors, recurarization, is another limitation 
of the currently used reversal strategy. Thus, there is clearly 
a clinical need for a new reversal agent, with minimal side-
effects and the capability to reverse neuromuscular blockade 
effectively, independently of its depth.
Sugammadex is the ﬁ  rst selective relaxant binding agent 
(SRBA) and has been designed to reverse the steroidal 
neuromuscular blocking drug rocuronium (Booij et al 2002; 
Bom et al 2002; de Boer et al 2006a). Sugammadex, per-
6-(2-carboxyethylthio)-per-6-deoxy-γ-cyclodextrin sodium 
salt (Figure 1), is a synthetic γ-cyclodextrin (CD) derivative 
designed to bind selectively to the steroidal NMBA molecule 
(Booij et al 2002; Bom et al 2002; de Boer et al 2006a). Cyclo-
dextrins, a group of cyclic oligosaccharides, are ring-shaped 
molecules with lipophilic inner cavities and hydrophilic 
outer surfaces that form complexes by inclusion of speciﬁ  c 
guest molecules, such as steroids (Bom et al 2002; Challa 
et al 2005). Structurally, they consist of either 6 (α-CDs), 
7 (β-CDs), or 8 (γ-CDs) glucose units and each type has its 
own characteristics (Challa et al 2005). CDs are highly water 
soluble, particularly γ-CDs compared with α- and β-CDs and 
are also biologically well tolerated (Bom 2002). Chemically 
modiﬁ  ed CDs have been used in the clinic to increase the 
stability, solubility, and bioavailability of an encapsulated 
drug, thereby delivering the required dose of the drug to the 
appropriate target sites (Bom et al 2002). The use of a modiﬁ  ed 
CD to reverse a rocuronium-induced neuromuscular blockade, 
by removing rocuronium from the effector site, thus represents 
a paradigm shift from current methodology. Encapsulation of 
the rocuronium molecule by sugammadex results in a rapid 
decrease in free rocuronium in the plasma and subsequently at 
the nicotinic receptor at the motor endplate (Figure 2). After 
encapsulation, rocuronium is not available to bind to the nico-
tinic receptor in the neuromuscular junction. This promotes the 
liberation of acetylcholine receptors, and muscle activity reap-
pears (Bom et al 2002; Epemolu et al 2003). This new concept 
of reversal of neuromuscular block induced by rocuronium 
(or vecuronium) led to impressive results in animal and phase 
1 and 2 studies. Sugammadex is currently in phase 3 clinical 
studies and may be commercially available by 2008.
Animal studies
The efﬁ  cacy of sugammadex as a reversal agent was evalu-
ated using different animal models (mouse, guinea pig, cat, 
and Rhesus monkeys). In vitro studies by Miller and Bom 
(2001), in the isolated mouse hemidiaphragm, showed that 
sugammadex effectively reversed a 90% neuromuscular 
block induced by the steroidal NMBAs agents rocuroni-
um, rapacuronium (no longer commercially available), 
vecuronium, and pancuronium. Most efﬁ  cient reversal was 
seen in the rocuronium-treated group followed by a neuro-
muscular block induced by rapacuronium, vecuronium, and 
pancuronium. However, sugammadex was not effective 
against the non-steroidal NMBAs mivacurium, atracurium 
and succinylcholine (Miller and Bom 2001). These ﬁ  ndings 
were conﬁ  rmed by Mason and Bom (2001) who performed 
in vivo experiments in guinea pig. In this study guinea pigs 
were treated with steroidal and non-steroidal NMBAs to 
induce a 90% neuromuscular block. The time of spontane-
ous recovery from this neuromuscular block was compared 
with the recovery time of the same neuromuscular block 
after the administration of 1.0 mg/kg sugammadex. The 
results showed that sugammadex caused a rapid reversal 
of neuromuscular block induced by steroidal NMBAs. No 
signs of residual blockade or recurarization were observed. 
The injection of sugammadex did not cause signiﬁ  cant 
changes in heart rate or blood pressure. In this study, they 
conﬁ  rmed and extended earlier ﬁ  ndings that sugammadex 
was not effective in reversing neuromuscular block induced 
by non-steroidal NMBAs. This conﬁ  rms that the size of the 
cyclodextrin cavity is too small to accommodate the bulky 
molecules of mivacurium and atracurium. Another study by 
Hope and colleagues evaluated the effects of sugammadex 
on rocuronium-induced steady-state neuromuscular block of 
the tibialis muscle of the anesthetized cat (Hope and Bom 
2003). A neuromuscular block of 90% was rapidly reversed 
by 1.0 mg/kg sugammadex, without signiﬁ  cant changes in 
heart rate and blood pressure and again no signs of residual 
blockade or recurarization were reported. Epemolu et al 
(2002) found in experiments in guinea pigs that the high 
afﬁ  nity of sugammadex for rocuronium results in a concen-
tration gradient between the free rocuronium molecules in 
the tissue compartment, including the effect compartment 
(neuromuscular junction) and the central compartment 
(plasma). As result of this concentration gradient free 
rocuronium molecules will return to the central compartment 
and are encapsulated by unsaturated sugammadex. Due to 
this process rocuronium is less available at the effect site, 
the neuromuscular junction and in turn muscle activity will 
return. de Boer et al (2006a) evaluated the capability of 
nine CD derivatives (one β-CD and eight γ-CDs of increas-
ing molecular weight) to reverse a constant neuromuscular Neuropsychiatric Disease and Treatment 2007:3(5) 541
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Figure 1 The chemical structure of sugammadex.
Figure 2 Complex formation of sugammadex and rocuronium as obtained by X-ray diffraction. The rocuronium molecule (model with spheres) is completely encapsulated 
by sugammadex (model with sticks).Neuropsychiatric Disease and Treatment 2007:3(5) 542
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block of 90% induced by rocuronium.The ability of these CD 
derivatives to reverse neuromuscular block was compared 
with the reversal of the same neuromuscular block by the 
commonly used combination of neostigmine and atropine. 
Furthermore the cardiovascular stability was evaluated by 
monitoring heart rate and blood pressure. The results of 
these experiments showed that two of the γ-CD derivatives 
(Org 26148 and Org 25969, sugammadex) caused a rapid 
and effective reversal of rocuronium-induced neuromuscular 
block versus spontaneous recovery without signs of residual 
blockade or recurarization. Both these CD derivatives were 
also signiﬁ  cantly faster and more efﬁ  cient compared with 
reversal by the currently used combination of neostigmine and 
atropine. There were no observable side-effects or signiﬁ  cant 
effects on blood pressure or heart rate caused by any of the nine 
synthetic CD derivatives. In contrast, in the experiments with 
neostigmine–atropine combination, two of the four animals 
showed abdominal discomfort (retching) and mean arterial 
pressure and heart increased signiﬁ  cantly to more than 10% 
of the baseline values in two of the four experiments. This 
study in Rhesus monkeys conﬁ  rmed earlier ﬁ  ndings in in 
vitro studies that the potency of natural α-, β-, and γ-CDs to 
reverse neuromuscular block induced by rocuronium correlates 
with their cavity sizes, resulting in a clear measurable effect 
for γ-CDs (Bom et al 2002; de Boer et al 2006a). The best ﬁ  t 
for cavity size can be improved by adding side chains to the 
molecules. The electric charge distribution in these side chains 
interacting with the charges in the guest molecule results in 
even greater afﬁ  nity. A rapid and effective reversal of 90% 
rocuronium-induced neuromuscular block could be achieved 
without signs of residual blockade or recurarization. However, 
little data about the reversal of profound neuromuscular block 
induced by rocuronium are available. The only study avail-
able on profound neuromuscular block was reported by Bom 
et al: they showed that a 10 × ED90 dose of rocuronium can 
be reversed by sugammadex in guinea pigs (Bom et al 2001). 
De Boer and colleagues designed a study to determine the 
feasibility of reversal of rocuronium-induced profound neu-
romuscular block in Rhesus monkeys (de Boer et al 2006b). 
A profound neuromuscular block was induced by injection of 
a 500 μg/kg dose of rocuronium (100 μg/kg resulted in a mean 
neuromuscular block of 93%). One minute after the adminis-
tration of rocuronium, either 1.0 or 2.5 mg/kg sugammadex or 
saline (placebo) was injected. The results of this study showed 
a signiﬁ  cant reversal of profound rocuronium-induced neuro-
muscular block after a dose of 2.5 mg/kg sugammadex and a 
partial reversal after 1.0 mg/kg sugammadex. Cardiovascular 
changes were not observed in this study.
Sugammadex-rocuronium complexes are highly hydro-
philic, and it has been demonstrated that sugammadex is 
excreted rapidly and dose dependently in urine of anesthetized 
guinea pigs (Epemolu et al 2002). Bom et al (2003) designed 
a study to determine the inﬂ  uence of renal impairment on 
the reversibility of rocuronium-induced neuromuscular block 
by sugammadex. This study showed that the effectiveness 
of sugammadex in reversal of neuromuscular block was 
not affected by cessation of renal blood ﬂ  ow. Furthermore 
acid-base imbalances were also studied to evaluate the 
effectiveness in changed circumstances (Mason et al 2002). 
The effectiveness of sugammadex was not affected by 
changes in pH in anesthetized guinea pigs.
Human studies
The ﬁ  rst human exposure of sugammadex was reported by 
Gijsenbergh et al (2005). Twenty-nine healthy male volun-
teers received either sugammadex or placebo. In the ﬁ  rst 
part of the study19 subjects received sugammadex up to 8.0 
mg/kg without administration of a neuromuscular blocking 
agent. In the second part of this study the subjects were 
anesthetized and received an intubation dose of 0.6 mg/kg 
rocuronium or placebo. This was followed by a single bolus 
injection of sugammadex (0.1–8.0 mg/kg) or placebo. As-
sessment of efﬁ  cacy showed a large reduction in recovery 
time as compared with placebo. A dose of sugammadex 
of 8.0 mg/kg resulted in a recovery time to a train-of-four 
ratio of 0.9 (normal neuromuscular function) of 1 minute 
compared with 52 minutes for placebo. Residual blockade 
or recurarization were not reported. There were no adverse 
events and sugammadex was well tolerated in doses up 
to 8.0 mg/kg. Shields et al (2006) studied sugammadex 
for reversal of prolonged (>2 hours) rocuronium-induced 
neuromuscular block. Thirty patients were anesthetised and 
received rocuronium 0.6 mg/kg as an initial dose followed 
by increments to maintain a deep block. Neuromuscular 
monitoring was carried out using acceleromyography, in the 
train-of-four mode. After at least 2 hours of neuromuscular 
block, at recovery of the second twitch of the train-of-
four, the patients received either sugammadex in a dose of 
0.5–6.0 mg/kg or placebo. The results showed a dose-related 
decrease in recovery time to a normal neuromuscular func-
tion (train-of-four ratio 0.9) within 2 minutes. No signs of 
recurarization were observed and no adverse events were 
reported. The conclusion of this study was that the effective 
dose to reverse a deep and prolonged rocuromium-induced 
neuromuscular block appears to be 2–4 mg/kg. Sorgen-
frei et al (2006) investigated the dose-response, safety, Neuropsychiatric Disease and Treatment 2007:3(5) 543
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and pharmacokinetics of sugammadex in a dose up to 4.0 
mg/kg in reversing neuromuscular block induced by 0.6 
mg/kg rocuronium. Sugammadex decreased the reversal 
time in a dose-dependent manner from 21.0 minutes in the 
placebo group to 1.1 minute in the 4.0 mg/kg sugammadex 
dose group. No signs of recurarization were observed and 
no adverse events were reported. Sugammadex enhanced 
renal excretion of rocuronium and was excreted unchanged 
in urine. Two patients experienced hypotension after the 
administration of 2.0 and 3.0 mg/kg sugammadex. These 
adverse events were considered to be possibly related to 
sugammadex. Reversal of high dose rocuronium (1.0 mg/kg) 
by sugammadex at 3 and 15 minutes after the administra-
tion of rocuronium was evaluated in a study by Khunl-
Bradey et al (2005). The patients were treated with either 
placebo or sugammadex in a dose up to 16.0 mg/kg. This 
study showed that a profound rocuronium-induced neuro-
muscular block was on average reversed within 2.5 minutes 
for a dose of 8.0 mg/kg sugammadex or higher. None of the 
reported adverse events were considered related to sugam-
madex. Another study investigated the efﬁ  cacy of sugamma-
dex in reversing rocuronium-induced neuromuscular block 
with either sevoﬂ  urane or propofol maintenance anesthesia 
(Vanacker et al 2005). After 2.0 mg/kg sugammadex, 
recovery to a normal neuromuscular function was equivalent 
under propofol and sevoﬂ  urane maintenance anesthesia. A 
multicenter dose-ﬁ  nding and safety study performed by de 
Boer et al (2005) investigated the reversal or rocuronium-
induced neuromuscular block by sugammadex at 5 min 
after the administration of rocuronium. After a high dose 
rocuronium (1.2 mg/kg) for intubation, the patients received 
either placebo or sugammadex in a dose op to 16.0 mg/kg 
5 minutes after the injection of rocuronium. A dose of 
sugammadex of 16.0 mg/kg resulted in a recovery time of 
less than 2 minutes compared with 122 minutes for placebo. 
Residual blockade or recurarization were not observed. 
Sugammadex caused a dose-dependent, fast, and efﬁ  cient 
reversal of profound rocuronium-induced neuromuscular 
block. Evaluation of safety data indicates that sugammadex 
was well tolerated at doses up to 16.0 mg/kg. Suy et al (2007) 
evaluated the dose-response relationship of sugammadex for 
the reversal of rocuronium and vecuronium-induced neu-
romuscular block. Thirty-nine patients received 0.6 mg/kg 
rocuronium and 40 received 0.1 mg/g vecuronium. Both 
groups were treated with either placebo or up to 8.0 mg/g 
sugammadex at reappearance of the second twitch of the 
train-of-four ratio. Again, a normal neuromuscular func-
tion was the primary end-point of this study. Sugammadex 
showed a fast and effective recovery after a rocuronium 
and vecuronium-induced neuromuscular block. A clear 
dose-response relationship was observed. Again, residual 
blockade or recurarization were not reported. No adverse 
events related to sugammadex were reported and sugamma-
dex showed a good safety proﬁ  le. A multicenter study further 
evaluated the efﬁ  cacy of sugammadex in reversing profound 
neuromuscular block induced by 1.2 mg/kg rocuronium (Rex 
et al 2005). Randomly at 3 or 15 minutes after the injection 
of rocuronium, sugammadex was administered in doses up 
to 16.0 mg/g. A dose-dependent time to recovery to a normal 
neuromuscular function was found. The reversal time was 
signiﬁ  cantly decreased compared with placebo. Only one 
adverse event was reported possibly related to sugammadex 
(QT-prolongation). An interesting study was conducted by 
Sacan et al (2006). Reversal of rocuronium-induced neu-
romuscular block by sugammadex was compared with the 
reversal of the currently used combination of cholinesterase 
inhibitors and muscarinic acetylcholine receptor antagonists, 
neostigmine-glycopyrrolate, and edrophonium-atropine. The 
reversal of rocuronium-induced neuromuscular block by 
sugammadex was more rapid and efﬁ  cient compared with 
neostigmine-glycopyrrolate and edrophonium-atropine. 
Treatment with sugammadex was also associated with 
fewer side-effects frequently reported after reversal with 
cholinesterase inhibitors.
Conclusion
The results of recent studies demonstrate that sugammadex 
is effective for reversal of rocuronium- and vecuronium-
induced neuromuscular block without apparent side-effects. 
This is in contrast to the currently available cholinesterase 
inhibitors used to reverse neuromuscular block, which are 
ineffective even against profound neuromuscular block and 
have a number of undesirable side-effects. Sugammadex–
rocuronium complexes are highly hydrophilic and it has 
been demonstrated that sugammadex is excreted in a rapid 
and dose-dependent manner in urine, resulting in a complete 
elimination from the body. Although sugammadex-induced 
reversal is tolerated in patients with renal disease, the fate of 
the sugammadex-rocuronium/vecuronium complex remains 
unclear. Clinical studies should be conducted in order 
to determine this. The ability of sugammadex to reverse 
rocuronium- and vecuronium-induced neuromuscular block 
may have major implications for routine anesthetic prac-
tice. Once sugammadex becomes commercially available, 
anesthesiologists will be capable of maintaining the desired 
depth of neuromuscular block at any time, thereby assuring Neuropsychiatric Disease and Treatment 2007:3(5) 544
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optimal surgical conditions. It has been speculated that 
sugammadex might also be used to rapidly terminate the 
effects of rocuronium in the dangerous and feared “cannot 
intubate, cannot ventilate” situation, and that it could improve 
the suitability of rocuronium rapid sequence induction tech-
niques. The mechanism by which sugammadex encapsulates 
rocuronium and vecuronium appears to be superior to cur-
rently used neuromuscular block reversal strategies in terms 
of speed, efﬁ  cacy, incidence of residual neuromuscular block 
and recurarization, and side-effects.
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